Which has stronger earnings and valuation, SNY or AZN?

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.08 $8.84B $3.58 11.84 Astrazeneca $60.44B 4.52 $10.23B $6.66 26.47

Is SNY or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to Sanofi's net margin of 16.95%. Astrazeneca's return on equity of 30.86% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to SNY or AZN?

In the previous week, Astrazeneca had 7 more articles in the media than Sanofi. MarketBeat recorded 11 mentions for Astrazeneca and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Astrazeneca's score of 0.30 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, SNY or NVS?

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.08 $8.84B $3.58 11.84 Novartis $54.53B 5.03 $13.98B $6.98 20.59

Is SNY or NVS more profitable?

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novartis 24.87% 38.82% 15.16%

Does the media refer more to SNY or NVS?

In the previous week, Novartis had 2 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Novartis and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Novartis' score of -0.13 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novartis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 16.95% 13.39% 7.58% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media favor SNY or NVO?

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Sanofi. MarketBeat recorded 36 mentions for Novo Nordisk A/S and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Novo Nordisk A/S's score of 0.74 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 22 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better earnings & valuation, GSK or SNY?

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.34 $7.54B $3.85 12.92 Sanofi $49.35B 2.08 $8.84B $3.58 11.84

Is GSK or SNY more profitable?

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Sanofi 16.95% 13.39% 7.58%

Does the media refer more to GSK or SNY?

In the previous week, GSK had 13 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for GSK and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat GSK's score of 0.49 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 8 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ARGX or SNY?

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 11.90 $1.29B $22.46 36.20 Sanofi $49.35B 2.08 $8.84B $3.58 11.84

Is ARGX or SNY more profitable?

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 33.28% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 33.28% 28.16% Sanofi 16.95% 13.39% 7.58%

Does the media favor ARGX or SNY?

In the previous week, argenex had 3 more articles in the media than Sanofi. MarketBeat recorded 7 mentions for argenex and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat argenex's score of 0.63 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sanofi (SNY) Competitors

$42.37 -0.43 (-1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$42.75 +0.38 (+0.90%)

As of 04:33 PM Eastern

Compare

SNY vs. AZN, NVS, NVO, GSK, and ARGX

Should you buy Sanofi stock or one of its competitors? MarketBeat compares Sanofi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanofi include Astrazeneca (AZN), Novartis (NVS), Novo Nordisk A/S (NVO), GSK (GSK), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does Sanofi compare to Astrazeneca?

Sanofi (NASDAQ:SNY) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Astrazeneca had 7 more articles in the media than Sanofi. MarketBeat recorded 11 mentions for Astrazeneca and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Astrazeneca's score of 0.30 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi presently has a consensus target price of $51.00, indicating a potential upside of 20.37%. Astrazeneca has a consensus target price of $205.33, indicating a potential upside of 16.48%. Given Sanofi's higher possible upside, equities analysts clearly believe Sanofi is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84
Astrazeneca	$60.44B	4.52	$10.23B	$6.66	26.47

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Astrazeneca has a net margin of 17.19% compared to Sanofi's net margin of 16.95%. Astrazeneca's return on equity of 30.86% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Astrazeneca	17.19%	30.86%	12.68%

Summary

Astrazeneca beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novartis?

Sanofi (NASDAQ:SNY) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84
Novartis	$54.53B	5.03	$13.98B	$6.98	20.59

In the previous week, Novartis had 2 more articles in the media than Sanofi. MarketBeat recorded 6 mentions for Novartis and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Novartis' score of -0.13 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sanofi has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Novartis has a net margin of 24.87% compared to Sanofi's net margin of 16.95%. Novartis' return on equity of 38.82% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novartis	24.87%	38.82%	15.16%

Sanofi currently has a consensus price target of $51.00, suggesting a potential upside of 20.37%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 1.74%. Given Sanofi's stronger consensus rating and higher possible upside, research analysts clearly believe Sanofi is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Novartis beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to Novo Nordisk A/S?

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Sanofi. MarketBeat recorded 36 mentions for Novo Nordisk A/S and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat Novo Nordisk A/S's score of 0.74 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	22 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 4.2%. Sanofi pays out 49.2% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84
Novo Nordisk A/S	$46.80B	4.01	$15.51B	$4.26	9.87

Sanofi has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Sanofi presently has a consensus price target of $51.00, suggesting a potential upside of 20.37%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 55.90%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Sanofi compare to GSK?

GSK (NYSE:GSK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

15.7% of GSK shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GSK has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Sanofi	16.95%	13.39%	7.58%

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.34	$7.54B	$3.85	12.92
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 6.55%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 20.37%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.89
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

In the previous week, GSK had 13 more articles in the media than Sanofi. MarketBeat recorded 17 mentions for GSK and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat GSK's score of 0.49 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	8 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. GSK pays out 47.0% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

GSK beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Sanofi compare to argenex?

argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

argenex presently has a consensus target price of $1,019.50, suggesting a potential upside of 25.38%. Sanofi has a consensus target price of $51.00, suggesting a potential upside of 20.37%. Given argenex's stronger consensus rating and higher probable upside, equities research analysts clearly believe argenex is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 33.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Sanofi	16.95%	13.39%	7.58%

argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.90	$1.29B	$22.46	36.20
Sanofi	$49.35B	2.08	$8.84B	$3.58	11.84

In the previous week, argenex had 3 more articles in the media than Sanofi. MarketBeat recorded 7 mentions for argenex and 4 mentions for Sanofi. Sanofi's average media sentiment score of 0.81 beat argenex's score of 0.63 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.3% of argenex shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

argenex beats Sanofi on 13 of the 16 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNY vs. The Competition

Export

Metric	Sanofi	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$102.72B	$298.67B	$6.25B	$12.42B
Dividend Yield	4.11%	2.82%	2.69%	5.29%
P/E Ratio	11.84	26.89	22.28	24.19
Price / Sales	2.08	4.77	581.86	138.32
Price / Cash	6.08	12.80	42.31	57.88
Price / Book	1.27	7.59	9.84	6.72
Net Income	$8.84B	$11.61B	$3.57B	$337.19M
7 Day Performance	-4.64%	-4.00%	-1.15%	0.53%
1 Month Performance	-8.05%	-1.86%	3.85%	5.10%
1 Year Performance	-13.86%	18.14%	27.43%	34.36%

Sanofi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNY Sanofi	4.7362 of 5 stars	$42.37 -1.0%	$51.00 +20.4%	-13.0%	$102.72B	$49.35B	11.84	74,846
AZN Astrazeneca	4.0283 of 5 stars	$179.90 -3.1%	$205.33 +14.1%	+23.3%	$287.96B	$58.74B	20.05	96,100	Analyst Forecast
NVS Novartis	3.1595 of 5 stars	$145.64 -3.0%	$141.20 -3.0%	+22.8%	$286.55B	$54.53B	20.86	75,267
NVO Novo Nordisk A/S	4.2011 of 5 stars	$44.01 -3.4%	$65.56 +49.0%	-41.0%	$203.51B	$46.80B	10.33	69,505	Trending News
GSK GSK	2.6811 of 5 stars	$49.23 -2.6%	$53.00 +7.6%	+17.9%	$102.56B	$43.07B	12.79	66,841	Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNY) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Competitors